Onespacemedia helps boost digital communication for pioneering biotech specialist

Press Release published by Onespacemedia, under Marketing, Strategy, User Experience

Cambridge web design and development specialist, Onespacemedia, has launched a new website for early-stage biotechnology company, Exonate.

Nottingham University spinout, Exonate, is developing a revolutionary, game changing eye drop for the treatment of retinal vascular diseases, including wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies. It’s Exonate’s mission to develop a unique, low side-effect treatment that can significantly improve patients’ quality of life.

Onespacemedia was hired to elevate Exonate’s profile within the market, and change the way that the company’s science and strategy are communicated. The new website showcases the company’s pioneering technology and presents their investors and key members of the advisory board, helping to build trust in the company and drive online business development and partnership enquiries.

The progressive design is centred around a grid structure with a unique ‘collage’ effect, drawing users’ attention to key areas. A news module helps the company to gather momentum through thought leadership, and attracts future employees.

James Cotton, founder and MD at Onespacemedia said,

It’s a pleasure to work with companies that are demonstrating such a pioneering approach to medical science. Exonate are working to transform the lives of those suffering from vision loss and we are delighted to have worked with them to create a website that showcases and explains their innovative science using the latest digital design trends and techniques.

Commenting on the website Exonate’s CEO Dr Catherine Beech, said,

Working with Onespacemedia has been a really positive experience. They have taken time to truly understand the science behind our Company and designed a modern, expansive and first-class website that emphasises Exonate’s corporate branding and supports our mission to profoundly improve the lives of those suffering from vision loss.

Subscribe to the CW newsletter

This site uses cookies.

We use cookies to help us to improve our site and they enable us to deliver the best possible service and customer experience. By clicking accept or continuing to use this site you are agreeing to our cookies policy. Learn more

Start typing and press enter or the magnifying glass to search